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Abstract
Background: Optimal management of locally recurrent prostate cancer after definitive radiation therapy is still
challenging. With the development of highly accurate radiotherapy devices, prostate salvage re-irradiation might
generate lower toxicity rates than classical salvage therapies. We retrospectively evaluated the toxicity and the
feasibility of a prostate re-irradiation after definitive radiation therapy failure. Two modalities were investigated:
high-dose-rate brachytherapy (HDRB) on whole prostate gland and focal stereotactic radiotherapy (SBRT) using
CyberKnife® linac.
Methods: Between 2011 and 2015, 28 patients with imaged and/or biopsy-proven intra-prostatic recurrence of
cancer after definitive radiation therapy underwent a salvage re-irradiation using HDRB (n = 10) or focal SBRT
(n = 18). The schedule of re-irradiation was 35 Gy in 5 fractions.
Biological response (defined as post-salvage radiation PSA variation) and biochemical no-evidence of disease
(bNED) were evaluated in the whole cohort. For patients who had a positive biological response after salvage
radiation, biochemical recurrence (BCR) and survival after salvage radiotherapy were evaluated. Post-salvage
toxicities were assessed according to the Common Terminology Criteria for Adverse Events (CTCAE) v4.03 and
were compared to baseline status.
Results: Within a median follow-up of 22.5 months (IQR = 8–42), 9 (90%) patients experienced a positive biological
response after salvage HDRB and 5 (50%) remained bNED at the end of the follow-up. Among patients who initially
responded to salvage HDRB, the BCR rate was 44.4% after a median interval of 19.5 months (IQR = 11.5–26). Only one
patient experienced a transient grade 3 urinary complication.
In the SBRT group, the median follow-up was 14.5 months (IQR = 7–23) and 10 (55.6%) out of the 18 patients remained
bNED. Among the 15 patients who initially responded to salvage SBRT, 5 (33.3%) experienced a BCR. One patient
experienced a transient grade 4 urinary complication.
At the end of the follow-up, all evaluated patients had a urinary status grade variation ≤ +1 grade. No grade 3–4
digestive toxicity was observed.
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Conclusions: Salvage prostate re-irradiation for locally recurrent cancer is feasible and generate low toxicities rates
when using with HDRB or focal SBRT. However, further investigations are necessary to confirm these findings and to
determine predictive features for patients who might benefit from such an approach.
Keywords: Prostate cancer, Local recurrence, Salvage therapy, High-dose-rate brachytherapy, Stereotactic body
radiation therapy, CyberKnife
Introduction
Although external beam radiation therapy (EBRT) and
brachytherapy are very efficient treatment modalities for
localized prostate cancer, more than the half of the pa-
tients would experience a biochemical recurrence (BCR)
within 10 years [1, 2]. Among these patients, about 20%
would present a local recurrence for which most of the
physicians would choose androgen-deprivation therapy
(ADT) as the cornerstone of the therapy management
[3]. But ADT remains a palliative treatment which sig-
nificantly impacts quality of life [4]. Furthermore, tumor
sensitivity to ADT is transient and cancer would eventu-
ally become castration-resistant. Therefore, preventing
or delaying the introduction of ADT after PSA failure
after initial treatment appears as a major challenge.
Local salvage procedures such as radical prostatectomy,
high-intensity ultrasounds ablation (HIFU), cryosurgery or
prostate re-irradiation [5–8] are therapy alternatives that
can be offered to highly selected patients. Prostate re-
irradiation was mainly done with low-dose-rate brachy-
therapy using seeds, with mixed results on efficacy and
toxicity [5, 9, 10]. However, recent improvement in radio-
therapy devices such as high-dose rate brachytherapy
(HDRB) and stereotactic body radiotherapy (SBRT) allow
to deliver higher ablative dose in a smaller target volume
with better sparing of surrounding critical organs at risk
[11, 12]. In spite of their encouraging results, very few pa-
tients benefit from these treatment options [3].
Actually, available data on post-radiation salvage HDRB
and SBRT are very sparse and heterogeneous. Reported 2-
year BCR-free survival are around 50% for both radiation
modalities [13–20]. The aim of this study was to evaluate
the clinical outcomes (efficacy and toxicity) of salvage
HDRB or SBRT (CyberKnife®, Accuracy, Sunnyvale, CA,




We retrospectively reviewed medical records of patients
treated with salvage HDRB or CyberKnife® for a post-
radiation prostate cancer local recurrence between 2011
and 2015 at Antoine-Lacassagne Cancer Center, Nice,
France and at Clinique Hartmann, Levallois-Perret,
France. All cases included in this study were discussed
and approved by a multidisciplinary team. All patients
provided a written informed consent for this institutions’
review boards-approved study. A total of 43 patients
were reviewed. Patients with proven lymph node and/or
distant metastasis at the time of salvage radiation (n = 9),
those who underwent another local treatment between
primary and salvage radiation (n = 3), and patients with a
follow-up shorter than 5 months (n = 3) were excluded
from the study, leaving 28 patients to be included for
final analysis (Fig. 1).
Follow-up after primary radiation
All patients experienced a BCR according to Phoenix
criteria (PSA nadir + 2 ng/mL) or 1997 ASTRO criteria
(three consecutive rises of PSA level above the nadir).
Imaging investigations following BCR included pelvic
and prostatic MRI (T2-weighted, diffusion-weighted and
dynamic contrast-enhanced), [11C]-choline positron emis-
sion computed tomography (PET-CT) and thorax, ab-
dominal and pelvic CT-scan. The indications of prostate
biopsy or ADT were retained after multidisciplinary dis-
cussion of each case. Salvage re-irradiation was considered
only in patients with a relapse delay > 24 months after
initial radiation and a life-expectancy > 10 years. Prostate
biopsies were required before considering local salvage
therapy. However, in case of histological impossibility to
determine a precise Gleason score but with pathological
features of malignancy together with a body of evidence in
favor of a local recurrence (PSA kinetic, prostate MRI and
[11C]-PET-CT findings) patients remained eligible for
salvage radiation. Post-radiation complications were re-
corded using the Common Terminology Criteria for
Adverse Events (CTCAE v4.03) [21].
Salvage radiation modalities
Stereotactic body radiation therapy protocol
Salvage SBRT was delivered with a CyberKnife® accelerator
(Accuray, Sunnyvale, CA, USA). For tracking modality, at
least three gold fiducials were placed in the prostate via
trans-rectal ultrasonography (TRUS). Then, patients
underwent a non-contrast-enhanced multi-slice CT scan
(GE LightSpeed Scanner, GE Healthcare Diagnostic
Imaging, Slough, UK) with 1.25 mm slice thickness.
Patient immobilization during CT acquisition and treat-
ment was obtained by a custom-build holding device.
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Prostate index tumor was defined by MRI and/or [11C]-
choline PET and was considered as the gross tumor vol-
ume (GTV). The GTV was delineated by using image fu-
sion of MRI and/or [11C]-choline PET with planning CT.
Assuming that the clinical target volume (CTV) would be
the GTV plus a 1-mm margin, the planning target volume
(PTV) was delineated as the CTV plus a 1-mm margin
leading to consider a focal SBRT. On each slice, con-
touring of organs at risk (rectum, bladder and femoral
heads) were also performed. All plans were optimized
using Multiplan® treatment planning system (Accuray,
Sunnyvale, CA, USA). The PTV received 35 Gy in 5
fractions of 7 Gy each in 5 consecutive days within the
80% coverage dose. The dose constraints for organs at risk
were applied according to the American Association of
Physicists in Medicine recommendations [22].
High dose rate brachytherapy protocol
The method of HDRB has been previously described
[23]. Briefly, under general anesthesia and after urinary
catheterization, 17 HDRB trans-perineal vectors (Sharp
Needles™, Elekta AB, Stockholm, Sweden) were placed
under TRUS guidance. The whole prostate gland and, if
needed, the proximal part of the seminal vesicles were
implanted using a dedicated perineal template. Due to
vectors migration occurring after the implant [24], a new
CT-scan was performed before each fraction allowing a
specific re-planification and re-optimization of treatment
plans. The CTV was defined as the outer contour of
the prostate and included proximal part of the seminal
vesicles if necessary. A total dose of 35 Gy was delivered
in 5 fractions over 5 consecutive days. Urethra and rectum
were delineated as organs at risk. According to recom-
mendations of GEC/ESTRO [25], the following dose con-
strains for target volume were applied: the percentage of
CTV receiving 100% of the prescribed isodose (V100)
was ≥95%; V150 was limited to <30%, and V200 was
limited to <12%. The dose non-homogeneity ratio (DNR)
had to be <0.30. For the urethra, V115 was kept to <1%
and for the rectum, V80 was kept to <1%. For both SBRT
and HDRB, the doses received by organs at risk at initial
treatment were not taken into account.
Androgen deprivation therapy (ADT)
At the time of recurrence, ADT was dispensed to 2
(20.0%) patients that were further treated with salvage
HDRB and one (10.0%) of them did not discontinue his
treatment before salvage HDRB. In the SBRT group, 10
(55.6%) patients were receiving ADT before salvage
treatment and for 3 (16.7%) of them ADT was not with-
drawn after salvage SBRT.
Follow-up after salvage radiation and endpoints’
definitions
After salvage re-irradiation, PSA level dosage and clinical
assessment of toxicities according to the CTCAE v4.03
were recorded at 2 months after treatment, then every
3 months for a year, then every 6 months. For the purpose
of this study, biochemical response was defined according
to PSA level variation (ΔPSA) between pre-salvage and
Fig. 1 Patients’ flow chart
Mbeutcha et al. Radiation Oncology  (2017) 12:49 Page 3 of 10
post-salvage re-irradiation: biochemical positive response
was defined as a diminution of ΔPSA of more than 20%,
biochemical failure corresponded to ΔPSA progressing of
more than 20% and biochemical stabilization was defined
between these two ranges.
In case of biochemical failure, a new [11C]-choline-
PET-CT was performed to define local, regional or distant
failure. A systemic treatment (ADT or chemotherapy) was
introduced according to European Association of Urology
guidelines [7]. For patients who experienced biochemical
positive response or stabilization, post-salvage BCR was
defined according to Phoenix criteria taking post-salvage
PSA nadir level as a reference.
The primary endpoint was progression-free survival
defined as biochemical no evidence of disease (bNED).
For the group of patients who experienced a positive
biochemical response or stabilization after salvage re-
irradiation, other analyzed survival covariates were BCR-
free survival, local recurrence-free survival, lymph-node
recurrence-free survival, metastatic-free survival and sys-
temic therapy-free survival. Because some patients expe-
rienced late effects of the primary irradiation at the time
of BCR and in order to assess the specific effect of pros-
tate re-irradiation on organs at risk (urethra and rectum),
acute (<3 months) and late (>3 months) toxicities were
expressed as grade variations compared to baseline status
using CTCAE v4.03 [21].
Statistical analyses
Continuous variables were expressed with median and
interquartile range and were compared using the
Kruskal-Wallis test. Categorical variables were compared
with the χ2 test. Survival probabilities were estimated by
the Kaplan-Meir method. Cases were censored at the
last follow-up. A p-value < 0.05 was considered signifi-
cant. Statistical analyses were carried out using Stata v11
(College Station, TX, United States).
Results
Patients’ characteristics
Finally, within a median follow-up of 15.5 months (IQR =
7–28), 28 patients were included in this study. Among
them, 10 patients underwent HDRB while 18 patients
underwent SBRT (Fig. 1). Table 1 summarizes patients’
characteristics at primary treatment and at recurrence.
Patients treated with salvage SBRT had mainly received
low-dose-rate brachytherapy (83.3%) for low-risk group of
D’Amico initial prostate cancer (55.6%), whereas the
HDRB group was mainly constituted of patients with ini-
tial high-risk disease (70.0%) treated with EBRT (90.0%)
(p = 0.006 and p < 0.001, respectively). The median time
to BCR was 69 months (IQR = 55–85) and 49 months
(IQR = 37–70) for HDRB and SBRT groups, respectively
(p = 0.11). There was no significant difference of delay
between primary and salvage radiation in both groups
(86.5 months (IQR = 66–108) vs. 77 months (IQR = 64–92)
for HDRB and SBRT respectively, p = 0.26).
Oncologic outcomes after salvage high-dose-rate
brachytherapy
Ten patients underwent salvage HDRB within a median
follow-up of 22.5 months (IQR = 8–42) and 5 (50%)
remained bNED at the end of the follow-up. Dosimetric
features of HDRB are resumed in Table 2a. The median
PSA level at the time of salvage HDRB was 4.42 ng/mL
(IQR = 2.01–6.7). Nine (90%) patients had a biochemical
positive response with a median ΔPSA of -2.81 ng/mL
(IQR = -5.6;-1.16) and 1 (10%) patient experienced a bio-
chemical progression despite salvage HDRB. For patients
who responded to salvage HDRB (n = 9, 90%), median
PSA nadir was 0.66 ng/mL (IQR = 0.23–1.13) and was
reached within 6 months (IQR = 5–8) after salvage
radiation. Among patients who initially experienced bio-
chemical positive response to HDRB (n = 9, 90%), 4
(44.4%) of them experienced BCR within 19.5 months
(IQR = 11.5–26) after salvage therapy (Fig. 2). Three
(33.3%) patients experienced image-proven loco-regional
disease recurrence within 27 months (IQR = 14–36) and
2 patients (22.2%) experienced metastatic disease pro-
gression within a median time interval of 25 months
(IQR = 14–36). When including patients who did not
interrupted their ADT, median time before the introduc-
tion of systemic treatment was 14 months (IQR = 6–27).
With a follow-up of 21 months, the patient who experi-
enced immediate HDRB biochemical failure did not
developed extra-prostatic disease progression after intro-
duction of ADT.
Oncologic outcomes after salvage stereotactic body
radiation therapy
Within a median follow-up of 14.5 months (IQR = 7–23),
10 (55.6%) out of the 18 patients who underwent salvage
SBRT remained bNED. SBRT dosimetric characteristics
are resumed in Table 2b. The median PSA level at the
time of salvage SBRT was 4.5 ng/ml (IQR = 3.0–5.3).
Thirteen patients (72.2%) presented a regression of PSA
level after salvage SBRT with a median ΔPSA of
-3.2 ng/mL (IQR = -5.34; -1.8), 2 patients (11.1%) had a
PSA level stabilization and 3 (16.7%) patients experienced
post-SBRT biochemical failure. When considering patients
who had a positive response or stabilization (n = 15), nadir
PSA level was 1.00 ng/mL (IQR = 0.42–2.4) and was
reached within 7.5 months (IQR = 4.5–10) after sal-
vage SBRT. Five patients (33.3%) experienced BCR
within a median follow-up of 7 months (IQR = 4–7)
(Fig. 2). Among them, 3 patients (20.0%) experienced
loco-regional disease recurrence within 5 months (IQR =
4.9–9.5) and 1 (6.7%) had a metastatic progression of his
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Table 1 Patients’ characteristics
Characteristics High-dose-rate brachytherapy
(n = 10)
Stereotactic body radiation therapy
(n = 18)
p value p value
Primary treatment (%) Recurrence (%) Primary treatment (%) Recurrence (%) Primary Recurrence
Age (years, median, IQR) 63 (58–68) 69 (65–77) 62 (58–66) 69 (64–75) 0.87 0.85
PSA at the time of treatment
(ng/mL, median, IQR)
26 (8.6–47) 4.37 (2.01–4.76) 6.6 (5.7–9.2) 4.5 (3.0–6.3) 0.0046 0.43
Initial T stage - - 0.005
T1c 2 (20.0) 12 (66.7)
T2a 2 (20.0) 2 (11.1)
T3 6 (60.0) 2 (11.1)
Not evaluated - 2 (11.1)
Initial Gleason sum 0.04 0.71
Gleason 6 or less 2 (20.0) 1 (10.0) 13 (72.2) 2 (11.1)
Gleason 7 4 (40.0) 2 (20.0) 4 (22.2) 2 (11.1)
Gleason 8 4 (40.0) 1 (10.0) 1 (5.6) 1 (5.6)
Gleason 9 - 2 (20.0) - 2 (11.1)
Not evaluated - 4 (40.0) - 11 (61.1)
D’Amico risk group 0.006
Low 1 (10.0) - 10 (55.6) -
Intermediate 2 (20.0) 5 (27.8)
High 7 (70.0) 2 (11.1)
Not evaluated - 1 (5.6)
Tumor localization 0.21 0.019
Apex - 1 (10.0) -
Median - - 2 (11.1) 2 (11.1)
Basis - 3 (30.0) 1 (5.6) 1 (5.6)
Seminal vesical 1 (10.0) - - 7 (38.9)
More than 1 location 1 (10.0) 6 (60.0) 3 (16.7) 3 (16.7)
Not evaluated 8 (80.0) 1 (10.0) 12 (66.7) 4 (22.2)
Initial ADT duration - - 0.0031
Short (6 months) 2 (20.0) 7 (38.9)
Long (24–36 months) 5 (50.0) 1 (5.6)
No ADT 3 (30.0) 10 (55.6)
ADT at recurrence - - 0.05
Yes 2 (20.0) 10 (55.6)
No 8 (80.0) 8 (44.4)
ADT duration (months, median, IQR) - 63.5 (48–79) - 15 (6–21) 0.028
Initial radiation modality - - <0.001
LDR brachytherapy 1 (10.0) 15 (83.3)
EBRT w/o pelvic radiation 5 (50.0) 3 (16.7)-
EBRT with pelvic radiation 4 (40.0)
Prostate volume (cc, median, IQR) 33.5 (32–35) 35 (20–50) 35 (25–44.5) 26 (22.5–28.5) 0.78 0.59
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disease. All the 3 patients who experienced a post-SBRT
biochemical failure developed an extra-prostatic evolution
despite the introduction of ADT.
Toxicities after salvage radiation
Toxicities following salvage radiation are summarized in
Tables 3.
During the course of HDRB and within 3 months
thereafter, most patients experienced grade 1–2 toxic-
ities (Table 3a). When comparing to baseline, 2 patients
(20%) had no modification of their acute urinary status,
3 (30%) experienced an increase of +1 grade and 4 (40%)
of +2 grades.
When considering late toxicities, 5 patients (50%) had
a urinary condition worsen of +1 grade and 1 patient (10%)
had a +2 grade worse condition (Table 3b). One (10%) pa-
tient experienced a grade 3 hematuria 12 months after sal-
vage HDRB, treated by hyperbaric chamber. No grade 3–4
digestive toxicity occurred during the follow-up.
After salvage SBRT, no patient experienced grade 3–4
digestive toxicity (Table 3c). One patient (5.6%) experi-
enced a septic shock following a prostatitis complicated
by a histology-proven prostate necrosis 12 months after
salvage SBRT. This patient already had a history of pros-
tatitis and underwent several transurethral resections of
the prostate for benign prostatic obstruction. At last
follow-up, 12 patients (66.7%) had no modification of
their urinary and digestive status compared to baseline
(Table 3d).
Discussion
Despite its wide range of side effects and the absence of
curative perspective, ADT remains the most chosen op-
tion in case of local recurrence of prostate cancer after
definitive radiation therapy [3, 4]. However, international
guidelines also consider the possibility to offer a local sal-
vage therapy to some patients who meet the criteria of a
strictly intra-prostatic disease [7]. For these highly selected
patients (PSA < 10 ng/ml, Gleason score ≤ 7, PSA doubling
time ≥ 16 months and life expectancy > 10 years), a salvage
treatment modality can be proposed in order to control
the local disease, and delay, or better still, suppress the in-
dication of ADT.
Due to the reluctance of physicians to intervene on
potentially vulnerable tissues, local salvage options are
hardly ever proposed to patients [3]. In this context,
salvage prostate re-irradiation can only be considered
and investigated if this option is associated with low
toxicity rates.
Therefore, in this retrospective study, we evaluated the
toxicity and the feasibility of a prostate re-irradiation
after definitive radiation therapy failure. Two modalities
were investigated: HDRB and SBRT using CyberKnife®.
Available data on salvage re-irradiation with HDRB are
sparse and were mainly limited by their heterogeneity
for both the type of patients included and the radiation
protocols used [13–16, 26]. Furthermore, they were
Table 1 Patients’ characteristics (Continued)
PSA nadir (ng/mL, median, IQR) 0.065 (0.01–0.2) 0.66 (0.23–1.13) 0.58 (0.34–1.05) 0.89 (0.29–1.4) 0.0034 0.97
Time to PSA nadir (months, median, IQR) 21 (16–30) 6 (5–8) 28 (11–35) 7.5 (4.5–10) 0.79 0.89
Time to biological recurrence
(months, median, IQR)
69 (55–85) 13 (10–26) 49 (37–70) 5.5 (4–6) 0.11 0.0347
Time to salvage treatment
(months, median, IQR)
86.5 (66–108) - 77 (64–92) - 0.26
Note: PSA prostate specific antigen, ADT androgen deprivation therapy, IQR interquartile range, LDR low-dose-rate, EBRT external beam radiotherapy
Table 2 Dosimetric features for high-dose-rate brachytherapy









D2 rectum 57 (50–69)
D2 urethra 81 (76–85)
DHI 0.27 (0.22–0.33)
b
Region of interest Mean (cGy) Min (cGy) Max (cGy)
GTV 4027 3462 4375
PTV 3936 3134 4375
Bladder 862 161 3680
Rectum 727 102 3561
Right femoral head 371 145 894
Left femoral head 428 139 1075
Note: CTV clinical target volume, D90 dose delivered to 90% of the CTV, D100
dose delivered to 100% of the CTV, V100 volume receiving 100% of the
prescribed dose, V150 volume receiving 150% of the prescribed dose, V200
volume receiving 200% of the prescribed dose, D2 rectum dose delivered to
2% of the rectum volume, D2 urethra dose delivered to 2% of the urethra
volume, DHI dose non-homogeneity Index: V150/V100
Note: GTV gross target volume, PTV planning target volume
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often conducted on small cohorts. However, reported 2-
year bNED or BCR-free survivals ranged from 50 to
89%. To date, only one prospective study is available. In
this phase II study, Yamada et al. treated 42 patients
with a total dose of 32 Gy in 4 fractions [17]. Within a
median follow-up of 36 months, 68.5% remained free of
BCR.
After definitive radiation therapy for the primary pros-
tate cancer, late grade 1–2 and 3–4 urinary complica-
tions are about 17% and 3%, respectively. For digestive
toxicity, 15% of the patients would experience grade 1–2
complications and 2% of them would experience grade
3–4 adverse events [27]. Logically, at the time of local
salvage re-irradiation on potentially weakened tissues,
higher morbidity rates are expected whatever the chosen
option is. This is also true for salvage prostatectomy
which is associated with the highest rates of complica-
tions, even if it remains the most efficient option for
oncologic outcomes [28–30]. Whole prostate gland cryo-
surgery and low-dose-rate brachytherapy with seeds have
similar survival rates with HDRB, but are associated with
poorer functional outcomes [28, 30]. Indeed, the most
recently published protocols of HDRB were associated
with a grade 3 urinary complication rate between 2
and 20%, with almost none severe digestive complica-
tions [13, 15–17, 26]. With a bNED rate of 50% after
22.5 months of median follow-up and very low severe
toxicity rates, our results on salvage HDRB are very en-
couraging and are comparable to published data. In this
context, it is worth proposing a prostate re-irradiation to
some highly selected patients.
To date, only few studies have been published on salvage
re-irradiation using a CyberKnife® linac. Vavassori et al.
published the first results on prostate re-irradiation using
this system. In this preliminary retrospective case series in-
cluding 6 patients treated with a total dose of 30 Gy in 5
fractions on the whole prostate gland, 2 patients remained
bNED after 11.2 months of median follow-up [18]. Since
then, Fuller et al. published a retrospective study including
29 patients treated with a total dose of 34 Gy in 5 fractions
within a median follow-up of 24 months. They reached
an actuarial 2-year BCR-free survival of 82% with only
7% of grade 3–4 urinary toxicity and no severe digestive
toxicity [20].
Our approach for salvage SBRT was slightly different
as we used focal re-irradiation instead of whole gland
treatment. We reached a bNED rate of 55.6% at
14.5 months of median follow-up and a BCR-free sur-
vival of 66.7% with reasonable induced toxicity. Janoray
et al. recently published a report on focal salvage SBRT
using CyberKnife® after EBRT failure [31]. In this retro-
spective study including 11 patients, they reached a bio-
chemical response rate of 82% (9 out of 11 patients). At
twelve months of follow-up, 6 patients were free of dis-
ease recurrence. Our results on survival outcomes are
similar to those obtained by other focal salvage therapies
such as cryosurgery, HIFU or low-dose-rate brachyther-
apy. Reported 1-year BCR-free survival ranged from 69
to 100% and dropped to 49–100% at 2-year [32]. Severe
reported urinary and digestive toxicities ranged from 0
to 33.3%. In our study, most of the patients had transient
low-grade complications and returned to baseline at the
last follow-up.
Therefore, both salvage HDRB and focal SBRT appear
as suitable options to delay the introduction of ADT in
some highly selected patients, without exposing patients
Fig. 2 Biochemical recurrence-free survival after salvage high-dose-rate brachytherapy (n = 10) and stereotactic body radiation therapy (n = 18)
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Table 3 Complication grades and grade variations following salvage high-dose-rate brachytherapy (a, b) and stereotactic body
radiation therapy (c, d) using CTCAE v4.03
a
HDRB At baseline Maximal acute toxicity Maximal late toxicity At last follow-up
Urinary complication (n, %)
No complication 5 (50.0) - 2 (20.0) 2 (20.0)
Grade 1 4 (40.0) 2 (20.0) - 3 (30.0)
Grade 2 1 (10.0) 7 (70.0) 6 (60.0) 5 (50.0)
Grade 3 - - 1 (10.0) -
Grade 4 - - - -
Not evaluated 1 (10.0) 1 (10.0) -
Digestive complication (n, %)
No complication 7 (70.0) 8 (80.0) 7 (70.0) 10 (100.0)
Grade 1 3 (30.0) 1 (10.0) 2 (20.0) -
Grade 2 - - - -
Grade 3 - - - -
Grade 4 - - - -
Not evaluated - 1 (10.0) 1 (10.0) -
b
HDRB At 3 months At last follow-up
n % n %
Urinary complication
No modification 2 20.0 4 40.0
+ 1 grade 3 30.0 5 50.0
+ 2 grades 4 40.0 1 10.0
Not evaluated 1 10.0 - -
Digestive complication
No modification 9 90.0% 10 100
+ 1 grade - - - -
+ 2 grades - - - -
Not evaluated 1 10.0% - -
c
SBRT At baseline Maximal acute toxicity Maximal late toxicity At last follow-up
Urinary complication (n, %)
No complication 8 (44.4) 2 (11.1) 6 (33.3) 4 (22.2)
Grade 1 5 (27.8) 5 (27.8) 4 (22.2) 6 (33.3)
Grade 2 3 (16.7) 2 (11.1) 1 (5.6) 3 (16.7)
Grade 3 1 (5.6) - - -
Grade 4 - - 1 (5.6) -
Not evaluated 1 (5.6) 9 (50.0) 6 (33.3) 5 (27.8)
Digestive complication (n, %)
No complication 13 (72.2) 5 (27.8) 9 (50.0) 10 (55.6)
Grade 1 1 (5.6) 1 (5.6) - 1 (5.6)
Grade 2 2 (11.1) 2 (11.1) 1 (5.6) 2 (11.1)
Grade 3 - - - -
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to an unreasonable risk of complication. But the scope
of our results is limited by the retrospective setting of
our study, its small cohort and its short follow-up that
make it not calibrated to establish cancer-specific and
overall survival rates. Furthermore, even if few patients
did not discontinue their ADT after salvage radiation,
this fact constitutes a bias for the interpretation of sur-
vival outcomes. Indeed, the heterogeneous population
including both hormone-refractory and hormone-naïve
prostate cancers together with both low- and high-grade
cancers probably impacted oncologic outcomes. There-
fore, the determination of predictive factors for radiation
sensitive cancers would help to refine the selection of
patients who could benefit from a salvage prostate re-
irradiation. These questions have been discussed during
the Delphi conference of consensus on salvage brachy-
therapy [33], but many crucial questions such as maxi-
mal PSA value at the time of salvage brachytherapy,
prostate gland volume to treat (whole gland, half or
focal) or radiation doses did not reach a consensus.
The choice to perform a focal radiation with Cyber-
Knife® has been encouraged by oncologic results of focal
cryosurgery and HIFU which were comparable to whole
gland treatment with less toxicity [32]. But as all focal
treatments, the main limitation remains in the definition
of the target volume. Even if we used fusion of MRI and
[11C]-choline-PET, we can’t guaranty that the visualized
lesions are the only cancerous spots in the prostate.
But this study has also strengths: our hypo-fractionation
scheme for HDRB allowed, contrarily to most of the
studies published on this topic, to treat patients within 5
consecutive days with only one implant. This report on
salvage focal CyberKnife® shows promising results that
would worth to be confirmed in a larger and prospective
manner.
Conclusion
For highly selected patients, salvage prostate re-irradiation
using HDRB or focal SBRT are suitable options to treat
local recurrence of cancer after definitive radiation ther-
apy. The low toxicity rates associated with both of these
techniques are encouraging proposing these options to a
well-defined group of patients, without exposing them to
an unreasonable risk. However, further investigations are
needed to confirm these findings and to define selec-
tion criteria for patients who could benefit from such
approaches.
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Table 3 Complication grades and grade variations following salvage high-dose-rate brachytherapy (a, b) and stereotactic body
radiation therapy (c, d) using CTCAE v4.03 (Continued)
Grade 4 - - - -
Not evaluated 2 (11.1) 10 (55.6) 8 (44.4) 5 (27.8)
d
SBRT At 3 months At last follow-up
n % n %
Urinary complication
No modification 4 22.3 12 66.7
+ 1 grade 4 22.2 1 5.6
+ 2 grades 1 5.6 - -
Not evaluated 9 50.0 5 27.8
Digestive complication
No modification 7 38.9 12 66.7
+ 1 grade - - - -
+ 2 grades 1 5.6 - -
Not evaluated 10 55.6 6 33.3
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